Chardan Capital Maintains Buy on Ocugen, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Daniil Gataulin maintains a Buy rating on Ocugen (OCGN) and raises the price target from $4 to $5.
April 22, 2024 | 11:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital maintains a Buy rating on Ocugen and increases the price target from $4 to $5.
The upgrade in price target by Chardan Capital indicates a positive outlook on Ocugen's stock, suggesting potential upside. This is likely to influence investor sentiment positively in the short term, potentially leading to an increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100